Skip to content

Effect of enteral formula enriched with omega-3 fatty acid to prevention of weight reduction in patients with Parkinson's Disease

Effect of enteral formula enriched with omega-3 fatty acid to prevention of weight reduction in patients with Parkinson's Disease - Effect of enteral formula enriched with omega-3 fatty acid in patients with Parkinson's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008057
Enrollment
25
Registered
2012-06-06
Start date
2012-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Daily oral administration of enteral nutrition formula (Racol NF) 400ml for 12 weeks consecutively.

Sponsors

St. Mariannna University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged 35 years old and above and less than 80 years old at the time of informed consent. 2. Patients who have lost a weight 5% and above unintentionally within past 6 to 12 months. 3. Patients who are capable of consent and have given voluntary written informed consent. 4. Patients who have benefit of L-DOPA drug at the start of administration. 5. Patients who have administrated L-DOPA and DCA combination drugs more than 6 months consecutively. 6. Patients with stable dosage and administration of antiparkingon's disease drugs before 2 weeks of observation period. 7. Patients who are able to follow the study schedule.

Exclusion criteria

Exclusion criteria: 1. Patients with parkinsonian syndrome 2. Patients have participated in the other studies or clinical trials of enteral nutrition formula. 3. Patients who have received surgical treatment such as stereotactic neurosurgery within 6 months. 4. Patients with psychological symptom such as severe confusion, hallucination, delusion and abnormal behavior. 5. Patients with cognitive dysfunction (MMSE score is no more than 21) 6. Patients with a history of drug allergy (Including any ingredient of study drug) 7. Patients who have administrated other study drugs and drug of post-marketing clinical trial within 3 months before observation period and have not completed other studies at the time of informed consent 8. Patients judged to be inappropriate for the study by the investigator.

Design outcomes

Primary

MeasureTime frame
Body weight reduction rate ,amount of PD clinical evaluation scale score change (Total score by each part of UPDRS )

Secondary

MeasureTime frame
Change rate of albumin, prealbumin, acyl-ghrelin, desacyle-ghrelin, leptin

Countries

Japan

Contacts

Public ContactMakoto Shiraishi

St. Mariannna University School of Medicine Neurology

shira@marianna-u.ac.jp044-976-8516

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026